ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

DCPC Board Oks Concept For Three New Grant Programs, Three Contracts

May 22, 1987

In Brief: Caplan Receives NSB Public Service Award

March 28, 2014

In Brief: Cancer Panel To Meet Aug.29; RFP On Impact Of Planning Cancelled As Being “Premature“

August 15, 1980

Double Trouble For NIH: Democrats Offer Small Increases, Bush May Veto The Bill.

July 6, 2007

President’s FY 1987 Budget Trims NCI 473 Million From 1986 Appropriation; Basic Research Hit Hard

February 7, 1986

NCI/NTP Studies Found EDB Carcinogenic, But Risk To Human Said Not Conclusive

March 23, 1984